Trial reportNature communications2024
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.
5 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 65 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 6 pooled it
52.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label, Single Arm Phase II Study of Camrelizumab in Combination With Cisplatin and Nab-paclitaxel as a Novel Neoadjuvant Pre-Surgical Therapy for Resectable HNSCC
Intratumoral and Peritumoral Habitat Radiomics of MRI Predict Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy in Oral Squamous Cell Carcinoma
NCT07145931 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation
Tislelizumab Combined With Chemotherapy for Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Therapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base: A Prospective, Single-arm, Phase II Clinical Study
NCT07400094 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Prospective Non-Randomized Phase II Study of Neoadjuvant Camrelizumab Combined With Paclitaxel and Carboplatin in Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity and Larynx (Stage III-IVA)
NCT07791602 phase2active not recruitingnot on this mapstarted 2026, after this paper: background citation
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy (IDEAL-RT) in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Multicenter, Prospective, Phase II, Randomized Non-Inferiority Controlled Trial
Who cites it
65 citing papers in PubMed, 6 syntheses or guidelines pooled it, 90 citations in OpenAlex.
- Randomized Controlled Trials Comparing the Standard of Care to Alternative Treatments in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Literature Review.Advances in therapy · 2026Pooled it
- Timing of surgery after neoadjuvant immunochemotherapy in head and neck squamous cell carcinoma: Current evidence, surgical implications, and a research agenda.Oral and maxillofacial surgery · 2026Pooled it
- Progress in immunotherapy for resectable head and neck squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2025Pooled it
- Meta-analysis to Investigate the Correlation Between Event-Free Survival and Overall Survival in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma.Advances in therapy · 2025Pooled it
- Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II-IVa esophageal cancer: a network meta-analysis.Systematic reviews · 2025Pooled it
- Evaluating the efficacy and safety of different neoadjuvant immunotherapy combinations in locally advanced HNSCC: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study.Journal for immunotherapy of cancer · 2026Trial
- Pembrolizumab combined with nab-paclitaxel and platinum in recurrent/metastatic HNSCC: efficacy, safety, and survival predictive model.ESMO open · 2026Trial
- CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- An exploratory study of nimotuzumab combined with toripalimab and chemotherapy for locally advanced tonsillar cancer.Frontiers in immunology · 2026Trial
- Predictive value of [European journal of nuclear medicine and molecular imaging · 2025Trial
- Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial.Nature communications · 2025Trial
- Efficacy, safety and single-cell analysis of neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma: a phase II trial.Nature communications · 2025Trial
- Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial.Cell reports. Medicine · 2025Trial
- Efficacy and safety of the neoadjuvant chemoimmunotherapy with pembrolizumab plus docetaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck.Frontiers in immunology · 2025Trial
- Multicenter Prospective Phase II Study of Induction Therapy With Pembrolizumab, Cisplatin, and Fluorouracil in Patients With Locally Advanced Head and Neck Cancer.Cancer control : journal of the Moffitt Cancer CenterTrial
- Betel nut chewing influences pathologic response in oral squamous cell carcinoma treated by neoadjuvant immunochemotherapy.BMC cancer · 2026Article
- Review
- MRI-Based DeltaHabitat Radiomic Model Predicts Pathological Complete Response in Oral Cavity Cancer Treated With Neoadjuvant Chemoimmunotherapy.Cancer medicine · 2026Article
- Context-Dependent Role of GDF15: GDF15Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 3 institutions in 1 country.
Di Wu *Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.ORCID 0000-0002-6701-9545
Yong Li *Department of Pathology, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.ORCID 0009-0008-1080-7787
Pengfei Xu *Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.ORCID 0000-0002-1174-3630
Qi FangDepartment of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Fei CaoDepartment of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.ORCID 0000-0002-9568-2360
Hongsheng LinDepartment of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yin LiDepartment of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yong SuDepartment of Radiation Oncology, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicin, Guangzhou, China.
Lixia LuDepartment of Radiation Oncology, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicin, Guangzhou, China.
Lei ChenDepartment of Radiation Oncology, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicin, Guangzhou, China.
Yizhuo LiDepartment of Radiology, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Zheng ZhaoDepartment of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Xiaoyu HongNanjing Geneseeq Technology Inc, Nanjing, China.
Guohong LiNanjing Geneseeq Technology Inc, Nanjing, China.
Yaru TianJiangsu Hengrui Pharmaceuticals Co., LTD, Shanghai, China.ORCID 0000-0001-6315-1859
Jinyun SunJiangsu Hengrui Pharmaceuticals Co., LTD, Shanghai, China.
Honghong YanDepartment of Intensive Care Medicine, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yunyun FanDepartment of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Xinrui ZhangDepartment of Otolaryngology-Head and Neck Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. zxr-850@163.com.ORCID 0000-0002-9615-835X
Zhiming LiDepartment of Medical Oncology, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. lizhm@sysucc.org.cn.ORCID 0000-0001-9730-9917
Xuekui LiuDepartment of Head and Neck Surgery, Sun Yat-Sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. liuxk@sysucc.org.cn.ORCID 0000-0002-6635-1095
Sun Yat-sen University · CNJiangsu Hengrui Medicine (China) · CNGuangzhou Medical University · CN
Funding
China Postdoctoral Science Foundation No.2022M713612Natural Science Foundation of Guangdong Province (Guangdong Natural Science Foundation) No.2114050002549
Abstract
Neoadjuvant chemoimmunotherapy has emerged as a potential treatment option for resectable head and neck squamous cell carcinoma (HNSCC). In this single-arm phase II trial (NCT04826679), patients with resectable locally advanced HNSCC (T2‒T4, N0‒N3b, M0) received neoadjuvant chemoimmunotherapy with camrelizumab (200 mg), nab-paclitaxel (260 mg/m
Indexed as
AlbuminsAntibodies, Monoclonal, HumanizedCarcinoma, Squamous CellHead and Neck NeoplasmsPaclitaxelAntineoplastic Combined Chemotherapy ProtocolsCisplatinHumansImmunotherapyNeoadjuvant TherapySquamous Cell Carcinoma of Head and Neck130-nm albumin-bound paclitaxelAlbuminsAntibodies, Monoclonal, HumanizedcamrelizumabCisplatinPaclitaxel
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT04826679ClinicalTrials.gov
NCT06854107ClinicalTrials.gov
NCT07145931ClinicalTrials.gov
NCT07400094ClinicalTrials.gov
NCT07791602ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.